Immunotherapy-Chemo combo shows promise in aggressive lymphoma trial

NCT ID NCT03749018

Ongoing Disease control Sponsor: David Bond, MD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (DA-REPOCH) can improve outcomes for people with aggressive B-cell non-Hodgkin lymphoma. The study enrolls 30 patients with various subtypes of the disease. The main goal is to see how long patients live without their cancer progressing after this combination treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (an immunotherapy drug) combined with DA-REPOCH chemotherapy
What this could lead to: If successful, this could offer a more effective treatment option for aggressive B-cell lymphoma, potentially improving how long patients live without their cancer worsening.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply to everyone. Adding immunotherapy to chemo can also increase side effects like immune-related inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGGRESSIVE NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma high grade B-cell lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement indolent B-cell non-Hodgkin lymphoma mediastinal gray zone lymphoma non-Hodgkin lymphoma primary mediastinal large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGGRESSIVE NON-HODGKIN LYMPHOMA ANN ARBOR STAGE I PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA ANN ARBOR STAGE II B-CELL NON-HODGKIN LYMPHOMA ANN ARBOR STAGE II PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA ANN ARBOR STAGE III B-CELL NON-HODGKIN LYMPHOMA ANN ARBOR STAGE III PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA ANN ARBOR STAGE IV PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA DIFFUSE LARGE B-CELL LYMPHOMA HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 AND/OR BCL6 REARRANGEMENTS HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED INDOLENT NON-HODGKIN LYMPHOMA MEDIASTINAL B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE B-CELL LYMPHOMA AND CLASSIC HODGKIN LYMPHOMA TRANSFORMED NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.